Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

NCT03448718 is registered in ClinicalTrials.gov with Matthew Galsky as lead sponsor.

NCT NCT03448718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03448718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Lead sponsor
Matthew Galsky
Phase
Phase 2
Overall status
Completed
Start date
April 17, 2018
Completion date
October 15, 2021
Enrollment
19 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic urothelial cancer